Database Commons
Database Commons

a catalog of worldwide biological databases

Database Profile

General information

URL: https://idrblab.org/themarker
Full name: The database of therapeutic biomarkers
Description: TheMarker (a) systematically offers five types of therapeutic biomarker, which realized the collective consideration among different drug discovery stages, (b) comprehensively describes the therapeutic biomarker for the largest number of drugs among existing knowledge bases, and (c) extensively covers the largest classes of disease among available databases.
Year founded: 2024
Last update: 2024
Version: Release 1.0
Accessibility:
Manual:
Accessible
Real time : Checking...
Country/Region: China

Funding support

  • 82373790

Classification & Tag

Data type:
Data object:
Database category:
Major species:
Keywords:

Contact information

University/Institution: Zhejiang University
Address: College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
City: Hangzhou
Province/State: Zhejiang
Country/Region: China
Contact name (PI/Team): Feng Zhu
Contact email (PI/Helpdesk): zhufeng@zju.edu.cn

Publications

37850638
TheMarker: a comprehensive database of therapeutic biomarkers. [PMID: 37850638]
Zhang Y, Zhou Y, Zhou Y, Yu X, Shen X, Hong Y, Zhang Y, Wang S, Mou M, Zhang J, Tao L, Gao J, Qiu Y, Chen Y, Zhu F.

Distinct from the traditional diagnostic/prognostic biomarker (adopted as the indicator of disease state/process), the therapeutic biomarker (ThMAR) has emerged to be very crucial in the clinical development and clinical practice of all therapies. There are five types of ThMAR that have been found to play indispensable roles in various stages of drug discovery, such as: Pharmacodynamic Biomarker essential for guaranteeing the pharmacological effects of a therapy, Safety Biomarker critical for assessing the extent or likelihood of therapy-induced toxicity, Monitoring Biomarker indispensable for guiding clinical management by serially measuring patients' status, Predictive Biomarker crucial for maximizing the clinical outcome of a therapy for specific individuals, and Surrogate Endpoint fundamental for accelerating the approval of a therapy. However, these data of ThMARs has not been comprehensively described by any of the existing databases. Herein, a database, named 'TheMarker', was therefore constructed to (a) systematically offer all five types of ThMAR used at different stages of drug development, (b) comprehensively describe ThMAR information for the largest number of drugs among available databases, (c) extensively cover the widest disease classes by not just focusing on anticancer therapies. These data in TheMarker are expected to have great implication and significant impact on drug discovery and clinical practice, and it is freely accessible without any login requirement at: https://idrblab.org/themarker.

Nucleic Acids Res. 2024:52(D1) | 1 Citations (from Europe PMC, 2024-04-27)

Ranking

0
Citations
0
z-index

Community reviews

5 Stars (1)
Data quality & quantity:
Content organization & presentation
System accessibility & reliability:

Word cloud

Related Databases

Citing
Cited by

Record metadata

Created on: 2024-02-10
Curated by:
Lin Liu [2024-03-03]
Yintao Zhang [2024-02-10]